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Abstract
To understand brain function, it is essential that we discover how cellular signaling specifies 
normal and pathological brain function. In this regard, chemogenetic technologies represent 
valuable platforms for manipulating neuronal and non-neuronal signal transduction in a cell-type-
specific fashion in freely moving animals. Designer Receptors Exclusively Activated by Designer 
Drugs (DREADD)-based chemogenetic tools are now commonly used by neuroscientists to 
identify the circuitry and cellular signals that specify behavior, perceptions, emotions, innate 
drives, and motor functions in species ranging from flies to nonhuman primates. Here I provide a 
primer on DREADDs highlighting key technical and conceptual considerations and identify 
challenges for chemogenetics going forward.
Chemogenetics has been defined as a method by which proteins are engineered to interact 
with previously unrecognized small molecule chemical actuators (Forkmann and 
Dangelmayr, 1980; Sternson and Roth, 2014; Strobel, 1998). Over the past two decades, a 
large number of chemogenetic (also known as “chemical genetic”; (Bishop et al., 1998; 
Strader et al., 1991; Chen et al., 2005; Sternson and Roth, 2014) platforms have been 
invented that have been useful for biologists in general and most especially for 
neuroscientists.
A number of protein classes (Table 1) have been chemogenetically engineered including 
kinases (Bishop et al., 1998; Bishop et al., 2000; Chen et al., 2005; Cohen et al., 2005; Dar 
et al., 2012; Liu et al., 1998), non-kinase enzymes (Collot et al., 2003; Häring and Distefano, 
2001; Klein et al., 2005; Strobel, 1998), G protein-coupled receptors (GPCRs) (Alexander et 
al., 2009; Armbruster and Roth, 2005; Armbruster et al., 2007; Redfern et al., 1999; Redfern 
et al., 2000; Vardy et al., 2015), and ligand-gated ion channels (Arenkiel et al., 2008; 
Lerchner et al., 2007; Magnus et al., 2011; Zemelman et al., 2003) (for recent review, see 
Sternson and Roth, 2014). Of these various classes of chemogenetically engineered proteins, 
the most widely used to date have been Designer Receptors Exclusively Activated by 
Designer Drugs (DREADDs) (Armbruster and Roth, 2005; Armbruster et al., 2007), and this 
Neuron Primer is devoted to them.
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How an Understanding of GPCR Molecular Pharmacology Facilitates the 
Appropriate Use of DREADD Technology
Before discussing DREADDs in detail, I will first summarize essential foundational 
concepts of GPCR molecular pharmacology and signaling. This background information is 
essential for all readers so that they may understand how DREADDs may be most 
effectively used. According to classical models of GPCR action GPCRs exist in multiple 
ligand-dependent and -independent states. These multiple GPCR states range from “fully 
inactive” to “partially active” to “fully active” to “signaling complexes” (Roth and Marshall, 
2012; Samama et al., 1993). As depicted in Figure 1, GPCRs (R) are modulated by ligands 
(L) and can interact with both hetereotrimeric G proteins (G) and β-arrestins (βArr). 
According to the most recent findings, multiple inactive (e.g., “ground”) states exist that can 
be stabilized by ligands (R1L, R2L, and so on) or can even occur in the absence of ligands 
(R). Sodium ions stabilize the ground state by exerting a negative allosteric modulation via a 
highly conserved allosteric site (Fenalti et al., 2014; Katritch et al., 2014). Drugs that 
stabilize the R1L, R2L ground states function as inverse agonists (Samama et al., 1993, 
1994). Inverse agonists are also known as “antagonists with negative intrinsic activity” 
(Costa and Herz, 1989). The evidence for multiple GPCR states is supported by classical 
molecular pharmacological (Samama et al., 1993, 1994), biophysical (Gether et al., 1995), 
and structural studies (Manglik et al., 2015).
Both full and partial agonists stabilize the active state (R*L) and promote the formation of a 
signaling complex (e.g., the “ternary complex”) consisting of (1) the active receptor, (2) an 
agonist, and (3) the heterotrimeric G protein (R*LG) (De Lean et al., 1980; Samama et al., 
1993). In addition to the ligand-induced activation and inactivation of GPCRs, GPCRs can 
also spontaneously isomerize to an active state (R*) in the absence of ligand. Further, this 
active state can spontaneously interact with G proteins to yield a binary signaling complex 
in the absence of ligand (R*G) (Samama et al., 1993). This active state in the absence of 
ligand is termed “constitutive activity.”
GPCRs (R) also interact with arrestins (βArr) to form alternative signaling complexes (R**L 
and R**L βArr) (Luttrell et al., 1999; Wacker et al., 2013; Kroeze et al., 2015). GPCRs with 
high levels of basal (e.g., constitutive) activity can spontaneously interact with βArr to form 
an R**βArr complex in the absence of agonist (Marion et al., 2004; Kroeze et al., 2015). 
Based on high-resolution crystal structures of GPCR-arrestin complexes, the R*L βArr state 
appears to sterically occlude G-protein interactions with the receptor thereby abolishing G-
protein signaling (Shukla et al., 2014; Kang et al., 2015). Accordingly, the interaction of 
GPCRs with βArr also represents a “desensitized” or inactive G-protein state of the 
complex. At the single molecule level, when GPCRs are activated by agonists, they can 
couple to either G-proteins or arrestins, but not both. At the cellular level conformational 
ensembles of all of the states identified above exist. Biasing for one particular state is 
dependent upon both the cellular context and the available ligand (Vardy and Roth, 2013; 
Wacker et al., 2013).
A clear understanding of the implications of this extended and modified ternary complex 
model—for which there is now compelling biochemical (Strachan et al., 2014), biophysical 
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(Sounier et al., 2015; Nygaard et al., 2013), pharmacological (Weiss et al., 2013; Fenalti et 
al., 2014), and structural evidence (Fenalti et al., 2014; Manglik et al., 2015; Rasmussen et 
al., 2011; Wacker et al., 2013)—is crucial for understanding how GPCR-based 
chemogenetic technologies can be harnessed in neuroscience. Thus, for instance, a major 
concern for chemogenetic technologies is the possibility that high levels of expression of an 
engineered protein might have effects in the absence of chemical activation (Conklin et al., 
2008). Indeed, many of the second-generation chemogenetic GPCRs (e.g., receptors 
activated solely by synthetic ligands [RASSLs]) had high basal levels of activity leading to 
phenotypes in the absence of chemical actuators (Hsiao et al., 2008; Sweger et al., 2007).
As depicted in Figure 1, a GPCR with constitutive activity would be more likely to exist in 
the R* state and thus to spontaneously interact with G proteins to yield a signaling complex 
in the absence of ligand (R*G). As shown in Figure 2A, high levels of expression of a 
GPCR with constitutive activity leads to signaling in the absence of ligand. Although no 
studies to date have demonstrated a basal phenotype for any of the known DREADDs, it is 
important to express DREADDS at the lowest level consistent with experimental design. For 
hM3Dq (Alexander et al., 2009) and hM4Di (Zhu et al., 2014), life-long and extremely high 
levels of expression were attained using a genetically encoded tetracycline-sensitive 
induction system without basal electrophysiological, behavioral, or anatomical abnormalities 
being observed. More modest life-long expression of the Gs-DREADD (GsD) also was 
attained without any detectible electrophysiological, behavioral, or anatomical phenotype 
(Farrell et al., 2013). High levels of virally mediated expression of various DREADDs have 
yet not been reported to yield any significant basal phenotypes (Urban et al., 2015; Vardy et 
al., 2015; Denis et al., 2015; Isosaka et al., 2015; Hayashi et al., 2015). Of course, the 
absence of reports of basal activity does not imply the absence of basal activity. Going 
forward, if basal activity is observed, it would be prudent to simply lower the level of 
DREADD expression using (1) a lower titer of virus, (2) a weaker promotor, or (3) 
modifying post-transcriptional expression (e.g., deleting a woodchuck hepatitis virus 
[WPRE] element from the 3′ end of the construct). Thus, based on the law of mass action, 
decreasing [R] decreases the probability of [R]→[R*]→[R*G] (e.g., inactive, active, and 
signaling state) transitions.
An additional concern with DREADD technologies relates to issues of desensitization and 
subsequent receptor downregulation. Thus, following repeated dosing with a DREADD 
chemical actuator, one might observe diminished responses due to receptor desensitization 
and downregulation. This diminished response might be predicted because it is well known 
that GPCRs can be desensitized and subsequently internalized and downregulated following 
agonist-induced activation (DeWire et al., 2007).
As depicted in Figure 2A, the degree of desensitization depends greatly on the extent to 
which receptors are over-expressed and the subsequent amount of “receptor reserve.” 
“Receptor reserve” is a pharmacological term that describes the phenomenon whereby a 
maximum agonist response can be achieved with less than full occupancy of all of the 
receptors by agonists (Ruffolo, 1982). From a practical perspective, the concept of receptor 
reserve predicts that when DREADD expression is quite high, lower concentrations of the 
chemical actuator are needed to achieve a maximal response (Figure 2A). Additionally, 
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when receptors are desensitized or downregulated, there may be no change in the maximum 
response elicited by the agonist, but there may be a shift in the dose-response curve to the 
right because of receptor reserve (2A). Thus, when DREADDs are expressed at high levels 
relative to native GPCRs via viral or transgenic approaches, the cellular and behavioral 
responses will be less sensitive to repeated dosing than when they are expressed at lower 
levels. This phenomenon might explain why no significant desensitization was seen when 
DREADDs were virally or transgenically expressed (Alexander et al., 2009; Krashes et al., 
2011)
Another conceptual issue specific to DREADD technology relates to whether the effects 
observed regarding neuronal output and behavior occur due to canonical or non-canonical 
GPCR signaling. As shown in Figure 1, agonists may activate multiple downstream effector 
pathways, and it is likely that actions other than simply enhancing or silencing neural 
activity can result when DREADDs are activated. Specifically, one might be concerned 
about conditions in which βArr signaling is activated. To date, there have been no reports 
suggesting that the actions of the silencing (e.g., Gi-based DREADDs) or activating (e.g., 
Gq-based DREADDs) DREADDs on neuronal activity and subsequent physiological 
readouts could be explained by any mechanism other than altered neuronal firing. Pertinent 
to this issue, many studies have used DREADD and optogenetic technologies on the same 
neuronal populations. These studies have invariably identified essentially equivalent effects 
in terms of both the valence and magnitude of the effect on the physiological readout, 
although the duration is typically longer with DREADDs (Table 2 for representative 
examples). Indeed, many investigators now use both DREADD and optogenetic 
technologies to provide independent and converging lines of evidence in terms of both 
sufficiency and necessity when deconstructing neural circuits.
Current DREADDs
As shown in Table 1 (for recent reviews, see Sternson and Roth, 2014;Urban and Roth, 
2015; English and Roth, 2015), there now exist many GPCR-based chemogenetic tools. 
These include first- (“Alelle-specific GPCRs”; Strader et al., 1991), second-(RASSLs and 
“Engineered GPCRs”; Coward et al., 1998; Westkaemper et al., 1999), and third-generation 
(DREADDs; Armbruster and Roth, 2005; Armbruster et al., 2007) platforms. Currently, 
DREADDs are the most widely used chemogenetic tool; the available DREADDs are shown 
in Figure 3A.
Gq-DREADDS, CNO Analogues, and Basal Activity
For enhancing neuronal firing and activating Gq signaling in neuronal and non-neuronal 
cells, the hM3Dq DREADD is typically used (Alexander et al., 2009; Armbruster et al., 
2007). hM3Dq can be activated by clozapine-N-oxide (CNO)—a pharmacologically inert 
metabolite of the atypical antipsychotic drug clozapine (Armbruster et al., 2007; Roth et al., 
1994). When the original DREADDs were invented, three Gq-coupled DREADDs were 
created, each of which was based on a different human muscarinic receptor: hM1Dq, 
hM3Dq, and hM5Dq (Armbruster et al., 2007). All three Gq-DREADDs are activated by 
low nM concentrations of CNO and mobilize intracellular calcium (Armbruster et al., 2007). 
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All three Gq-DREADDs could be used as excitatory DREADDs, although hM3Dq appears 
to be most frequently used.
CNO (Figure 3B) represents the prototypical chemical actuator for Gq-DREADDs. Based 
on many reports, CNO appears to be pharmacologically and behaviorally inert in mice 
(Alexander et al., 2009; Krashes et al., 2011; Farrell et al., 2013; Guettier et al., 2009; Urban 
et al., 2015; Zhu et al., 2014) and rats (Ferguson et al., 2011, 2013) when administered at the 
recommended doses (generally 0.1–3 mg/kg). CNO may be metabolized via back-
transformation to clozapine—especially in guinea pigs, humans (Jann et al., 1994), and 
nonhuman primates (unpublished obsrevations). Although the amount of back-metabolism 
to clozapine is low even in humans (10% or less by mass; Jann et al., 1994), care should be 
taken to ensure that clozapine-like side-effects (e.g., hypotension, sedation, and 
anticholinergic syndrome) do not occur by keeping the dose as small as possible and by 
always performing appropriate controls (e.g., administering CNO to animals expressing GFP 
or similarly irrelevant protein).
CNO has excellent drug-like properties with rapid CNS penetration and distribution in mice 
(Bender et al., 1994). CNO appears to have at least a 60 min residence in vivo in mice 
following intraperitoneal administration (Bender et al., 1994). Given the long residence time 
of CNO, it is not surprising that the in vivo effects of CNO-mediated activation of hM3Dq 
can be both robust and prolonged (Alexander et al., 2009; Krashes et al., 2013). Clearly, 
unless long-term activation of Gq signaling and neuronal firing is needed, it is recommended 
that the lowest effective dose of CNO be administered so that only peak CNO 
concentrations activate the DREADD (Figures 2B and 2C). As can be seen in Figure 2B, 
when a large dose of CNO is administered, the effects of CNO may be greatly prolonged 
because brain levels of CNO remain higher than the threshold for activation of the 
DREADD receptor. By contrast, lower systemic doses of CNO (Figure 2C) would result in 
transient peak activation and then a relatively rapid decay of activity.
Because of the potential for back-metabolism of CNO to clozapine and other clozapine 
metabolites in non-rodent species—including the pharmacologically diverse compound N-
desmethyl-clozapine (NDMC) (Davies et al., 2005)—we have developed new non-CNO 
chemical actuators (Chen et al., 2015). The first of these—Compound 21 (Figure 3B)—has 
minimal off-target activity and exquisite selectivity for activating hM3Dq versus muscarinic 
and other GPCRs (Chen et al., 2015). Preliminary studies indicate that Compound 21 has 
equivalent potency in studies in vivo when compared with CNO (unpublished data). 
Compound 21 likely cannot be metabolized via normal routes to clozapine or any related 
compound and thus represents an alternative to CNO for studies in which back metabolism 
of CNO to clozapine is problematic.
An additional compound especially suited for translational studies is perlapine (Figure 3B), 
a drug that is approved for use in Japan for insomnia. Perlapine has >10,000-fold selectivity 
for activating hM3Dq versus muscarinic receptors with an EC50 at hM3Dq of 2.8 nM (Chen 
et al., 2015). Given perlapine’s modest affinity for some biogenic amine receptors (e.g., 5-
HT2A, 5-HT6, 5-HT7, and D4) (Davies et al., 2005; Roth et al., 1992, 1994, 1995), it is 
essential to test perlapine at the lowest possible dose in animals not expressing DREADDs 
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before embarking on studies involving DREADDs. These preliminary studies would ensure 
that off-target actions of perlapine do not interfere with the phenomena studied. Perlapine 
will likely find its greatest utility in translational studies of DREADDs in primates and, 
perhaps, in humans given that it is approved for use in humans. It is likely that further 
investigation of the scaffolds for compound 21 and perlapine will yield even more effective, 
potent, and selective chemical actuators for muscarinic-based DREADDs.
The first report that CNO-induced activation of hM3Dq depolarized and excited genetically 
defined neurons appeared in 2009 (Alexander et al 2009). Since then, hM3Dq has been 
widely used to enhance neuronal firing, and I here cite only representative examples in 
which feeding (Krashes et al., 2011; Atasoy et al., 2012), energy expenditure (Kong et al., 
2012), locomotion and striatal synaptogenesis (Kozorovitskiy et al., 2012), memory (Garner 
et al., 2012), and social behaviors (Peñagarikano et al., 2015) have been modulated by 
hM3Dq in vivo. Because hM3Dq activation induces intracellular calcium release, it has also 
been used to “activate” astrocytes (Agulhon et al., 2013; Bull et al., 2014; Scofield et al., 
2015), hepatocytes (Li et al., 2013), pancreatic βcells (Guettier et al., 2009; Jain et al., 2013), 
vascular smooth muscle cells (Armbruster et al., 2007), and iPS-derived neuroblasts 
(Dell’Anno et al., 2014).
Multiple options are currently available for expressing hM3Dq in genetically specified cells. 
Thus, genetically engineered mice are now available for expressing hM3Dq under control of 
tetracycline (tet-off) promotor (Alexander et al., 2009; Garner et al., 2012) and via Cre-
mediated recombination (Teissier et al., 2015) (Table 3); and some of these are available 
from Jackson Labs (Table 3). Many labs are using the FLEX switch (Schnütgen et al., 2003) 
as adapted by the Sternson lab for AAV (Atasoy et al., 2008) that allows for Cre-mediated 
cell-type-specific expression in any cell type for which there is a Cre-driver line available 
(Figure 4A). A key innovation for the development of AAV- and lentiviral-based FLEX 
switch vectors (also known as double-floxed inverse open reading frame [DIO]) (Gradinaru 
et al., 2010) was the use of separate antiparallel loxP-type recombination sites (especially 
loxP and lox2272) that allow for homotypic but not heterotypic recombination (Lee and 
Saito, 1998). In addition, a growing number of promotors have been characterized that allow 
for cell-type-specific expression using many viral vectors, including modified herpes 
simplex viruses (HSVs) (Ferguson et al., 2010), AAV (Zhu et al., 2014; Scofield et al., 
2015), and lentivirus (Mahler et al., 2014; Vazey and Aston-Jones, 2014). Finally, the use of 
canine adenovirus (CAV) expressing Cre-recombinase (CAV-Cre) allows for the projection-
specific expression of DREADDs. Projection-specific expression of DREADD is possible 
because CAV-Cre is preferentially retrogradely transported to neuronal somas. In the 
neuronal cell bodies, recombination of AAV-FLEX-DREADD constructs can occur to allow 
expression of DREADDs in a projection-specific fashion (Boender et al., 2014) (Figure 4B). 
The use of CAV-Cre and FLEX-DREADD constructs has been dubbed the “Retro-
DREADD” technique (Marchant et al., 2016) and in theory could be used for intersectional 
and multiplexed applications.
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Gi-DREADDs
To date there are three Gi-DREADDs: hM2Di, hM4Di, and KORD. Of these, hM2Di and 
hM4Di can be activated by CNO (Armbruster et al., 2007), compound 21, and perlapine 
(B.L. Roth, unpublished data). Currently, hM4Di is the most commonly used inhibitory 
DREADD (for review, see Urban and Roth, 2015). Many labs have reported successful 
neuronal silencing with hM4Di, and only representative reports are cited wherein 
DREADDs silenced neurons (Armbruster et al., 2007), modulated amphetamine 
sensitization (Ferguson et al., 2011) and synaptic plasticity (Kozorovitskiy et al., 2012), 
regulated breathing (Ray et al., 2011), feeding (Carter et al., 2013), itching (Bourane et al., 
2015), and emotional(Teissier et al., 2015) behaviors.
The κ-opioid-derived DREADD (KORD) is a new chemogenetic GPCR that is activated by 
the pharmacologically inert compound. Thus, salvinorin B has no activity at any other tested 
molecular target (>350 GPCRs, ion channels, transporters, and enzymes evaluated) and thus 
has no apparent off-target activity (Figure 3C) (Chavkin et al., 2004; Vardy et al., 2015). 
Salvinorin B does retain modest affinity for KOR (>100 nM) so that investigators using the 
KORD should use the lowest dose possible and verify no effects of salvinorin B in the 
absence of KORD. Several labs have reported successful inhibition of neural activity with 
KORD (Marchant et al., 2016; Vardy et al., 2015; Denis et al., 2015).
Both hM4Di and KORD appear to inhibit neuronal activity via two mechanisms: (a) 
induction of hyperpolarization by Gβ/γ-mediated activation of G-protein inwardly rectifying 
potassium channels (GIRKs) (Armbruster et al., 2007; Vardy et al., 2015) and (b) via 
inhibition of the presynaptic release of neurotransmitters (e.g., synaptic silencing) 
(Stachniak et al., 2014; Vardy et al., 2015). Thus, unlike bacterial opsins, which silence 
neurons via a strong hyperpolarization and with millisecond precision, DREADDs induce a 
modest hyperpolarization and an apparently strong inhibition of axonal release of 
neurotransmitter (Stachniak et al., 2014; Vardy et al., 2015) in the s-min-hr time frame. 
Because of the dependence upon Gβ/γ-mediated activation of GIRKs for inducing 
hyperpolarization, it is possible that hM4Di and KORD might not hyperpolarize all neurons. 
To date, there have been no reports that hM4Di or KORD fail to silence or inhibit neuronal 
activity.
Given that the Gi-coupled DREADDs have effects on terminal release the possibility that 
CNO (or an analogue) or SalB (or analogue) could micro-infused to locally suppress neural 
activity has been tested (Figure 4C). Thus, at least two groups (Stachniak et al., 2014; 
Mahler et al., 2014) have successfully silenced terminal projections via local infusion of 
CNO. Terminal axons have also been activated by local CNO infusion into rats expression 
hM3Dq (Vazey and Aston-Jones, 2014). For selective axonal silencing, an hM4Di variant 
has been created (Figure 3A; hM4Dnrxn) that is targeted preferentially to axons and axon 
terminals (Stachniak et al., 2014).
The availability of a new inhibitory DREADD—KORD—activated by a ligand orthogonal 
to CNO now allows for the multiplexed and bidirectional chemogenetic modulation of 
neural activity and behavior (Vardy et al., 2015). Thus, we recently demonstrated that 
KORD may be expressed simultaneously with hM3Dq to allow for the sequential 
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chemogenetic activation (with hM3Dq and CNO) and inhibition (with SalB and KORD) 
(Vardy et al., 2015) of neuronal activity (Figure 4D). It is likely that KORD and hM3Dq 
could be combined in a combinatorial fashion with various opsins and other chemogenetic 
tools (e.g., PSEM and PSAMs) to afford highly multiplexed control of neuronal activity 
with millisecond precision (e.g., with opsins) and for long periods of time for behavioral 
studies (e.g., with DREADDs or PSAMs).
Gs- and β-Arrestin-DREADDs
The only DREADD coupled to Gs was created by swapping the intracellular regions of the 
turkey erythrocyte β adrenergic receptor for equivalent regions of a rat M3 DREADD to 
create a rat Gs-DREADD (Guettier et al., 2009) (Figure 3A). Unlike the current Gq and Gi-
DREADDs, the Gs-DREADD (GsD) has a small degree of constitutive activity in 
transfected cells (Guettier et al., 2009) leading to a modest basal phenotype in pancreatic β 
cells (Guettier et al., 2009; Jain et al., 2013). Given that Gαolf is the major Gs-like Gα 
protein in some brain regions (Zhuang et al., 2000), it was critical to determine if GsD can 
also activate Gαolf. Importantly, we demonstrated that GsD efficiently couples to Gαolf in 
vitro and in vivo (Farrell et al., 2013) and that GsD had minimal constitutive activity for 
Gαolf-mediated signaling in vitro and in vivo (Farrell et al., 2013). GsD has been used by 
several groups to probe the role(s) of Gs-like signaling for a number of behaviors including 
ethanol consumption (Pleil et al., 2015), reward (Ferguson et al., 2013), locomotor 
sensitization (Farrell et al., 2013), and circadian rythmns (Brancaccio et al., 2013).
Finally, a DREADD that apparently signals exclusively via β-arrestin has been developed 
(Nakajima and Wess, 2012) (Figure 3A). This β-arrestin-specific DREADD (Rq(R165L) has 
not yet been used in vivo but has the potential to illuminate specific behaviors downstream 
of β-arrestin signaling (for discussion, see Allen and Roth, 2011; Allen et al., 2011).
Areas for Enhancement of DREADD Technologies
Chemogenetic technologies are now widely used neuroscientists with publications appearing 
at the rate of one to two per day. To date, hM4Di (for silencing) and hM3Dq (for activating) 
neurons have been the most frequent used DREADDs. DREADDs have been used to 
modulate neural activity and behavior in flies (Becnel et al., 2013), mice (Alexander et al., 
2009), rats (Ferguson et al., 2011), and nonhuman primates (Eldridge et al., 2016). Although 
DREADD technology has clearly been useful, there are several ways in which the 
technological platform could be enhanced.
Outlook for New DREADDs and Chemical Actuators
In terms of creating new DREADDs, we have described a generic platform wherein human 
GPCRs can be expressed in yeast with engineered selectable markers and chimeric G 
proteins (Armbruster et al., 2007; Dong et al., 2010) and have used this platform to express 
dozens of human GPCRs (Huang et al., 2015b). In theory it should be possible to create new 
DREADDs by directed molecular evolution of human GPCRs using the prior yeast-based 
platforms (Armbruster et al., 2007; Dong et al., 2010; Huang et al 2015c).
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An alternative approach is to use structure-guided docking of drug-like and 
pharmacologically inert small molecules against GPCRs for which there are available 
structures. This structure-guided approach was used by us to create KORD (Vardy et al., 
2015). Currently there are many high-resolution structures of GPCRs including a 1.8 Å 
structure of the human δ-opioid receptor (Katritch et al., 2014), two serotonin receptors in 
partially active states (Wang et al., 2013), active and coupled states of the μ-opioid (Huang 
et al., 2015a), M1-muscarinic (Kruse et al., 2013), β2-adrenergic receptors (Rasmussen et 
al., 2011), and many other inactive state structures (Katritch et al., 2014). Additionally, my 
lab and collaborators have used these structures for the successful structure-guided 
discovery of novel small molecule modulators (Weiss et al., 2013; Carlsson et al., 2011; 
Shoichet and Kobilka, 2012; Huang et al., 2015c). It is thus possible that new DREADDs 
could be created using these sorts of approaches.
With regard to new small molecule actuators, it would be useful to identify other CNO- and 
salvinorin B analogues with (a) good drug-like properties, (b) excellent CNS penetrability, 
(c) clean off-target pharmacology, and (d) favorable pharmacokinetic and toxicological 
features (Arrowsmith et al., 2015). Additionally the availability of salvinorin B analogues 
which are water soluble—as salvinorin B is typically dissolved in dimethylsulfoxide—
would also be useful. The development of these sorts of tool compounds could be achieved 
via conventional medicinal chemistry approaches (Chen et al., 2015) and by new 
technologies developed by my lab and my collaborators. These new chemical biology 
technologies allow for the design and validation of novel drug-like molecules using a 
combination of in silicio and in vitro approaches (Keiser et al., 2009; Besnard et al., 2012; 
Huang et al., 2015c; Kroeze et al., 2015). Additionally, new chemical biology platforms that 
allow for the unbiased assessment of on- and off-target pharmacologies of chemical 
actuators across the GPCR-ome (Kroeze et al., 2015), kinome (Elkins et al., 2015), and other 
targets (Arrowsmith et al., 2015) are key to validating the specificity of DREADD ligands.
Other areas of enhancement for DREADD technology would include the design of 
DREADDs with differential neuronal subdomain-specific targeting. Thus, in addition to the 
axonal targeting DREADDs previously reported (Stachniak et al., 2014), cell body, 
dendritically targeted, and spine-specifically targeted DREADDs would all be broadly 
useful. Enhancing the diversity of signaling cascades to include G12/13, Go, Golf, and so on 
would also be highly valuable to the community. Here, structure-based approaches might be 
especially valuable. Finally, improving the temporal resolution via photo-caging DREADDs 
or via creation of DREADD antagonists would also be potentially highly useful—
particularly given the large number of laboratories currently using DREADD technology.
Potential Therapeutic Applications for Chemogenetics
Many therapeutic applications of DREADD-based therapeutics have been suggested, 
including diabetes (Jain et al., 2013), metabolic disorders (Li et al., 2013), Parkinson’s 
Disease (Dell’Anno et al., 2014), psychostimulant (Ferguson et al., 2011) and ethanol (Pleil 
et al., 2015) abuse, depression (Urban et al., 2015), post-traumatic stress disorder (Zhu et al., 
2014), intractable seizures (Kätzel et al., 2014), inflammatory disorders (Park et al., 2014), 
autism (Peñagarikano et al., 2015), and many other disorders (English and Roth, 2015). 
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DREADDs have been successfully expressed in nonhuman primates without apparent 
toxicity, and an exciting new report demonstrates that CNO-DREADDs can modulate 
circuitry, electrophysiology, and behavior in nonhuman primates (Eldridge et al., 2016). As 
AAV is a commonly used gene delivery platform in humans, the most likely viral vector for 
human studies would be AAV. In terms of the chemical actuator, given the fact that 
perlapine is an approved medication with a long history of safety in humans, it would be the 
most likely DREADD ligand for activating CNO-based DREADDs in humans. Although 
CNO has been given to humans without ill-effects, given its propensity for back-metabolism 
to clozapine and NDMC in humans, it might not be the first choice for translational studies. 
Salvinorin B has not been administered to humans, although salvinorin A—it’s precursor—
has been used in many human studies without any apparent toxicity. Going forward it would 
be valuable to identify additional drugs that are approved for use in humans to accelerate 
translation of DREADD technology to humans.
In summary, DREADDs have transformed basic and translational neuroscience research. 
The availability of multiple DREADDs activated by chemically and pharmacologically 
distinct actuators will continue to facilitate the multiplexed, chemogenetic interrogation of 
circuits and cell types involved in behavior, cognition, emotion, memory, and perception.
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Figure 1. A Modified and Extended Ternary Complex Model of GPCR Action
As shown in the top panel GPCRs (R) may interact with ligands (L), hetereotrimeric G 
proteins (G), and arrestins (βArr) and thereby form a variety of inactive (green boxes), active 
(orange and red boxes), and signaling complexes (blue and red boxes). The bottom panel 
shows a cartoon of the various signaling complexes for canonical G protein signaling (L) 
and β-Arrestin signaling (R).
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Figure 2. How Receptor Reserve and Constitutive Activity may Modify DREADD Actions In 
Vitro and In Vivo
(A) Simulations of receptor activity using a standard four-parameter logistic equation for 
GPCR activation, and variable receptor expression (DeLean et al., 1978) was used to 
simulate the effects of over-expression of a DREADD with constitutive activity (red 
circles); high receptor reserve, minimal constitutive activity (blue circles); high receptor 
reserve + desensitization (green circles); low expression and no receptor reserve (purple 
circles); and low expression, no receptor reserve, and desensitization (orange circles).
(B and C) Potential pharmacokinetic parameters of CNO following high (B) and lower (C) 
doses. The dotted red line indicates the threshold concentration required for activation of the 
DREADD in situ.
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Figure 3. Available DREADDs and Chemical Actuators
(A) The available DREADDs, their current accepted nomenclature, and the potential 
downstream neuronal effects of activation.
(B and C) (B) Shows the structures of currently available chemical actuators for CNO-based 
DREADDs, while (C) shows the structure of the KORD ligand salvinorin B.
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Figure 4. Potential Approaches for Cell- and Projection-Specific Modulation of Neuronal 
Activity Using DREADDs
(A) The standard approach whereby DREADDs are expressed in a cell-type-specific manner 
(either virally or transgenically) and then activated by systemic administration of chemical 
actuator.
(B) How a combination of cell-type-specific expression (e.g., localized injection of AAV-
FLEX-hSyn-DREADD) and projection-specific infusion of CAV-Cre allows for the 
projection-specific expression and activation of DREADDs.
(C) How local infusion of a chemical actuator provides for projection-specific effects with a 
limited area of activation.
(D) How distinct DREADDs may be expressed in a cell-type-specific fashion to afford 
multiplexed chemogenetic modulation of neural activity and physiology.
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Table 1
Representative Chemogenetic Technologies
Name Protein(s) Ligand Reference
Representative kinases
Allele-specific kinase inhibitors v-I388G Compound 3g Liu et al., 
1998
Analogue-sensitive kinases v-Src (I338G, v-Src-as1), c-Fyn 
(T339G, c-Fyn-as1), c-Abl 
(T315A, c-Abl-as2), CAMK IIα 
(F89G, CAMK IIα-as1) and CDK2 
(F80G, CDK2-as1)
K252a and PPI analogues Bishop et al., 
1998
Rapamycin-insensitive TOR 
complex 2
TORC2 V2227L BEZ235 Bishop et al., 
2000
ATP-binding pocket mutations 
in EphB1, EphB2 and EphB3
Ephb1T697G, Ephb2T699A, and 
Ephb3T706A
PP1 analogues Soskis et al., 
2012
ATP-binding pocket mutations 
of TrkA, TrkB and TrkC
TrkAF592A, TrkBF616A, and 
TrkCF617A
1NMPP1 and 1NaPP1 Chen et al., 
2005
Representative Enzymes
Metalloenzymes Achiral biotinylated rhodium-
diphosphine complexes
Collot et al., 
2003
Engineered transaminases Chemically conjugating a 
pyridoxamine moiety within the 
large cavity of intestinal fatty acid 
binding protein
Enhanced activity Häring and 
Distefano, 
2001
Representative GPCRs
Allele-specific GPCRs β2-adrenergic receptor, D113S 1-(3′,4′-dihydroxyphenyl)-3-methyl-L-butanone (L-185,870) Strader et al., 
1991
RASSL-Gi (receptors activated 
solely by synthetic ligands)
κ-opioid chimeric receptor Spiradoline Coward et 
al., 1998
Engineered GPCRs 5-HT2A serotonin receptor 
F340→L340
Ketanserin analogues Westkaemper 
et al., 1999
Gi-DREADD M2- and M4 mutant muscarinic 
receptors
Clozapine-N-Oxide Armbruster 
and Roth, 
2005; 
Armbruster 
et al., 2007
Gq-DREADD M1, M3, and M5- mutant 
muscarinic receptors
Clozapine-N-oxide Armbruster 
and Roth, 
2005; 
Armbruster 
et al., 2007
Gs-DREADD Chimeric M3-frog Adrenergic 
receptor
Clozapine-N-oxide Guettier et 
al., 2009
Arrestin-DREADD M3Dq R165L Clozapine-N-oxide Nakajima 
and Wess, 
2012
Axonally-targeted silencing hM4D-neurexin variant Clozapine-N-oxide Stachniak et 
al., 2014
KORD κ-opioid receptor D138N mutant Salvinorin B Vardy et al., 
2015
Representative Channels
GluCl Insect Glutmate chloride channel; 
Y182F mutation
Ivermectin Lerchner et 
al., 2007
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Name Protein(s) Ligand Reference
TrpV1 TrpV1 in TrpV1 KO mice capsaicin Arenkiel et 
al., 2008
PSAM Chimeric channels PSAMQ79G,L141S PSEM9S Magnus et 
al., 2011
PSEM PSAM-GlyR fusions PSEM89S; PSSEM22S Magnus et 
al., 2011
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Table 2
Examples for Apparent Equivalency of Chemo- and Optogenetic Modulation
Cell Type DREADD Opsin Electrophysiology Behavior
AgRP Neurons hM3Dq (Krashes et al., 
2011)
ChR2 (Aponte et al., 2011) Increased firing Enhanced feeding
ETV-1 subfornical area neurons hM3Dq (Betley et al., 
2015)
ChR2 (Betley et al., 2015) Increased firing Enhanced drinking
Medial entorhinal cortex cells hM4Di (Miao et al., 
2015)
Arch (Miao et al., 2015) Decreased firing Remapping place cells
PBN CGRP Projection neurons hM3Dq (Cai et al., 
2014)
ChR2 (Cai et al., 2014) Increased firing Diminished feeding
Orexin neurons hM4Di (Sasaki et al., 
2011)
Halorhodopsin 
(Tsunematsu et al., 2011)
Decreased firing Decreased wakefulness
Hippocampus hM4Di (Zhu et al., 
2014)
Arch (Sakaguchi et al., 
2015)
Decreased firing Suppression of contextual 
fear conditioning
Raphe serotonergic neurons hM3Dq (Urban et al., 
2015)
ChR2 (Ohmura et al., 
2014)
Increased firing Anxiogenic
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